Regeneron Pharmaceuticals is taking another shot at US Food and Drug Administration (FDA) accelerated approval for odronextamab in relapsed/refractory follicular lymphoma (r/r FL), with the agency ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as precipitously, it did improve, gaining 2% to $1 ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab for certain adults ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

Regeneron's gene therapy study shows improved hearing in children with congenital deafness Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of ...

Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with one of the most ...